Physician profile
Nicholas D Mosca
NPI 1225568777
$7,290.72
in general payments reported to CMS, 2019-2025
29 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.64 · 2021: $1,808 · 2022: $1,945 · 2023: $1,598 · 2024: $1,478 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,444.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,342.50 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,108.92 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $875.94 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $739.92 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $739.52 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Takeda Pharmaceuticals U.S.A., INC. | $332.94 | 2021-2025 | Trintellix |
| Amgen INC. | $308.07 | 2021-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $257.01 | 2021-2025 | |
| Antares Pharma, INC. | $214.52 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Merck Sharp & Dohme LLC | $209.78 | 2019-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.80 | 2021-2025 | Jardiance, Tradjenta |
| Biohaven Pharmaceuticals, INC. | $115.65 | 2021 | |
| Exact Sciences Corporation | $114.31 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $103.56 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $81.89 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $73.44 | 2021-2022 | |
| Boston Scientific Corporation | $72.94 | 2019 | |
| Mylan Specialty L.P. | $63.44 | 2021-2022 | |
| Eisai INC. | $62.52 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $59.86 | 2023-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.13 | 2023 | Xifaxan |
| Horizon Therapeutics Plc | $33.29 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.62 | 2023 | |
| Amarin Pharma, INC. | $18.24 | 2021 | |
| Nestle Healthcare Nutrition INC. | $18.08 | 2021 | |
| Relievant Medsystems, INC. | $17.50 | 2022 | |
| Halozyme INC | $16.93 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.72 | 2025 | Caplyta |
| Almatica Pharma LLC | $13.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Mosca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.